ICC panel rules in flu drug dispute
Peramivir, branded as Rapivab (Credit: Biocryst)
North Carolina-based Biocryst Pharmaceuticals has reported a favourable ICC award terminating its agreement with an Australian-owned company for licensing of the world’s first intravenous flu treatment.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.
Subscribe now